The Association of Weight With the Detection of Airflow Obstruction and Inhaled Treatment Among Patients With a Clinical Diagnosis of COPD

Chest

Volumn 146, Issue 6, 2014, Pages 1513-1520

  Collins, Bridget F ^a   Ramenofsky, David ^b   Au, David H ^a   Ma, Jun ^c   Uman, Jane E ^a   Feemster, Laura C ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SHORT ACTING DRUG; BRONCHODILATING AGENT;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BODY MASS; BODY WEIGHT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ERROR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SPIROMETRY; VETERAN; CLINICAL TRIAL; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; OVERWEIGHT; PROCEDURES; PUBLIC HOSPITAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, INHALATION; AGED; AIRWAY OBSTRUCTION; BODY MASS INDEX; BRONCHODILATOR AGENTS; COHORT STUDIES; DIAGNOSTIC ERRORS; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SPIROMETRY; VETERANS;

EID: 84964698885     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2759     Document Type: Article

References (39)

1. 1 Kochanek, KD, Jiaquan, X, Murphy, SL, Minino, AM, Kung, HC, Deaths: final data for 2009. Natl Vital Stat Rep 60:3 (2011), 1–117.
2. 2 Flegal, KM, Carroll, MD, Ogden, CL, Curtin, LR, Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:3 (2010), 235–241.
3. 3 Cecere, LM, Littman, AJ, Slatore, CG, et al. Obesity and COPD: associated symptoms, health-related quality of life, and medication use. COPD 8:4 (2011), 275–284.
4. 4 Zutler, M, Singer, JP, Omachi, TA, et al. Relationship of obesity with respiratory symptoms and decreased functional capacity in adults without established COPD. Prim Care Respir J 21:2 (2012), 194–201.
5. 5 Joo, MJ, Au, DH, Lee, TA, Use of spirometry in the diagnosis of chronic obstructive pulmonary disease and efforts to improve quality of care. Transl Res 154:3 (2009), 103–110.
6. 6 Celli, BR, MacNee, W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23:6 (2004), 932–946.
7. 7 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org, 2013 Updated. Accessed February 22, 2013.
8. 8 National Committee for Quality Assurance. The State of Healthcare Quality 2012, 2012, 45–46 Washington, DC: National Committee for Quality Assurance.
9. 9 Han, MK, Kim, MG, Mardon, R, et al. Spirometry utilization for COPD: how do we measure up?. Chest 132:2 (2007), 403–409.
10. 10 Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Oran Tech Rep Ser 894 (2000), 1–253.
11. 11 Hankinson, JL, Odencrantz, JR, Fedan, KB, Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159:1 (1999), 179–187.
12. 12 Raebel, MA, Malone, DC, Conner, DA, Xu, S, Porter, JA, Lanty, FA, Health services use and health care costs of obese and nonobese individuals. Arch Intern Med 164:19 (2004), 2135–2140.
13. 13 Mannino, DM, Buist, AS, Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370:9589 (2007), 765–773.
14. 14 Lee, TA, Bartle, B, Weiss, KB, Spirometry use in clinical practice following diagnosis of COPD. Chest 129:6 (2006), 1509–1515.
15. 15 Walters, JA, Walters, EH, Nelson, M, et al. Factors associated with misdiagnosis of COPD in primary care. Prim Care Respir J 20:4 (2011), 396–402.
16. 16 Prieto Centurion, V, Huang, F, Naureckas, ET, et al. Confirmatory spirometry for adults hospitalized with a diagnosis of asthma or chronic obstructive pulmonary disease exacerbation. BMC Pulm Med, 12, 2012, 73.
17. 17 Must, A, Spadano, J, Coakley, EH, Field, AE, Colditz, G, Dietz, WH, The disease burden associated with overweight and obesity. JAMA 282:16 (1999), 1523–1529.
18. 18 Güder, G, Brenner, S, Angermann, CE, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res, 13(1), 2012, 13.
19. 19 Adams, KF, Schatzkin, A, Harris, TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355:8 (2006), 763–778.
20. 20 Barr, RG, Celli, BR, Martinez, FJ, et al. Physician and patient perceptions in COPD: The COPD Resource Network Needs Assessment Survey. Am J Med, 118(12), 2005, 1415.
21. 21 Salinas, GD, Williamson, JC, Kalhan, R, et al. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis 6 (2011), 171–179.
22. 22 Walker, PP, Mitchell, P, Diamantea, F, Warburton, CJ, Davies, L, Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J 28:5 (2006), 945–952.
23. 23 Crim, C, Calverley, PM, Anderson, JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34:3 (2009), 641–647.
24. 24 Lee, TA, Pickard, AS, Au, DH, Bartle, B, Weiss, KB, Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 149:6 (2008), 380–390.
25. 25 Singh, S, Loke, YK, Furberg, CD, Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300:12 (2008), 1439–1450.
26. 26 Ernst, P, Gonzalez, AV, Brassard, P, Suissa, S, Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176:2 (2007), 162–166.
27. 27 Gershon, A, Croxford, R, Calzavara, A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 173:13 (2013), 1175–1185.
28. 28 Restrepo, RD, Alvarez, MT, Wittnebel, LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 3:3 (2008), 371–384.
29. 29 Lipworth, BJ, Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159:9 (1999), 941–955.
30. 30 Guhan, AR, Cooper, S, Oborne, J, Lewis, S, Bennett, J, Tattersfield, AE, Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55:8 (2000), 650–656.
31. 31 Tashkin, DP, Multiple dose regimens. Impact on compliance. Chest 107:5_Supplement (1995), 176S–182S.
32. 32 Quesenberry, CP Jr, Caan, B, Jacobson, A, Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 158:5 (1998), 466–472.
33. 33 Martinez, CH, Kim, V, Chen, Y, et al. COPDGene Investigators. The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respir Med 108:3 (2014), 491–499.
34. 34 Qaseem, A, Wilt, TJ, Weinberger, SE, et al. American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 155:3 (2011), 179–191.
35. 35 Fujimoto, K, Kitaguchi, Y, Kubo, K, Honda, T, Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology 11:6 (2006), 731–740.
36. 36 Ora, J, Laveneziana, P, Ofir, D, Deesomchok, A, Webb, KA, O'Donnell, DE, Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. Am J Respir Crit Care Med 180:10 (2009), 964–971.
37. 37 Salome, CM, King, GG, Berend, N, Physiology of obesity and effects on lung function. J Appl Physiol (1985) 108:1 (2010), 206–211.
38. 38 Joo, MJ, Sharp, LK, Au, DH, Lee, TA, Fitzgibbon, ML, Use of spirometry in the diagnosis of COPD: a qualitative study in primary care. COPD 10:4 (2013), 444–449.
39. 39 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO workshop report. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org/uploads/users/files/GOLDWkshp2001.pdf, 2013 Published 2001. Accessed September 17.